Craig Marshall Chief Executive Officer Read more
Craig joined OrganOx in December 2016, and took over the role of CEO from Dr Les Russell in January 2017.
Prior to joining OrganOx, Craig was Managing Director of the award-winning business Siemens Magnet Technology. During the period 2010—2016, he was also an executive member of the Siemens Healthcare MRI business, the undisputed market leader. During his time in these roles, Siemens Magnet Technology developed a revolutionary new magnet contained within the World's strongest clinical MRI system, the Siemens MRI 7 Tesla product, MAGNETOM Terra.
Craig is a fellow of the Institution of Mechanical Engineers, he holds a first degree from the University of Liverpool, and an MBA with Distinction from the acclaimed University of Warwick Business School.
Earlier in his career, he worked at Oxford Instruments, Amersham Plc and GE Healthcare in a variety of management and leadership roles, within the in vivo diagnostics sector.
Peter Friend Chief Medical Officer Read more
Peter is OrganOx Co-Founder and Chief Medical Officer, and has worked with Constantin and the OrganOx team for more than 20 years on the development of OrganOx's normothermic organ perfusion technology. Peter leads OrganOx's pre-clinical and clinical programmes of OrganOx's patented normothermic organ perfusion technology.
Peter is Professor of Transplantation at the University of Oxford and Director of the Oxford Transplant Centre, where he is responsible for the kidney, small bowel and pancreatic transplant programmes. Earlier in his career Peter was Clinical Director of the Transplant Centre at Addenbrooke’s Hospital, Cambridge, one of the UK’s leading liver transplant centres and visiting Assistant Professor of Surgery at Indiana University Medical Centre, USA, where he established their liver transplant programme.
Peter's research interests lie primarily in novel applications of normothermic organ perfusion, ranging from its use for extracorporeal support to preservation and repair prior to transplantation. He has published over 25 papers on the topic of normothermic perfusion, the basis of the OrganOx technology, as well as in the areas of clinical transplantation, immunosuppression, monoclonal antibodies, xenotransplantation, liver perfusion and aspects of general surgery.
Constantin Coussios Chief Technical Officer Read more
Constantin is OrganOx Co-Founder and Chief Technical Officer and has worked with Peter and the OrganOx team for more than 20 years on the development of OrganOx's normothermic organ perfusion technology. Constantin leads OrganOx's technical development programmes.
Constantin is Professor of Biomedical Engineering at the University of Oxford and Director of the Oxford Institute of Biomedical Engineering. Constantin founded and heads the Biomedical Ultrasonics, Biotherapy and Biopharmaceuticals Laboratory (BUBBL), he is also the Director of the Oxford Centre for Drug Delivery Devices (OxCD3).
Constantin's research interests include normothermic organ perfusion, drug delivery, acoustic cavitation and therapeutic ultrasound. Constantin received the 2017 Royal Academy of Engineering Silver Medal and was appointed as a Fellow of the Royal Academy of Engineering in 2019.
Graham Yeatman Chief Financial Officer Read more
Graham joined OrganOx as Chief Financial Officer in June 2019. He has significant experience of being part of a senior leadership team for growth SMEs, implementing financial controls & procedures for managing significant change and growth, building capability and infrastructure, driving profitability, cash generation and value inflection. Graham has been in life sciences since 2006 and has undertaken two IPOs, numerous fundraisings (raising approx. £100m at hVIVO) and negotiated a number of complex licensing transactions and joint ventures.
Graham started his career with PricewaterhouseCoopers for 13 years, qualifying as a Chartered Accountant and working across its audit, tax, consultancy, business process re-engineering and outsourcing divisions. In 2001 he joined buyingTeam Limited (subsequently renamed Proxima) as Finance & Operations Director and was influential in growing the business to become one of the UK’s leading purchasing services providers. From 2006 to 2010 he was at Neuropharm Group plc as Chief Financial Officer. From 2011 to 2018 he was at hVIVO plc (formerly Retroscreen Virology Group plc) as Chief Financial & Business Officer. Graham has a first-class BSc in Economics and Maths from the University of Bristol.
Andy Self Global Commercial Director Read more
Andy joined OrganOx in February 2014. He has over 15 years experience in senior commercial roles in the both the Medtech and Biotech sectors. Prior to joining OrganOx Andy worked for Oxford University Innovation, the technology transfer company of the University of Oxford, with responsibilities for commercialization of life sciences Intellectual Property developed at the University. Andy started his career at the CRO BioFocus (now part of Charles River Laboratories International Inc.), in both scientific and commercial roles.
Toni Day Global Director of Quality and Regulatory Affairs Read more
Toni joined OrganOx in April 2011. Toni holds a BSc Honours degree in Biochemistry and a DPhil in Neuropharmacology from Oxford University.
Previously, Toni has worked for a number of start-up companies in the medical device, in vitro diagnostics and pharmaceutical arenas.
Most recently, Toni served 7 years at Oxford Immunotec Ltd, starting as a Senior Scientist working alongside the CEO and then through promotion to Director of Product Development, with line management responsibilities for 12 scientists and senior scientists. Toni has 11 years' experience in product development and regulatory submissions for both European and US approval.
Daniel Voyce Technical Director Read more
Daniel has a BEng in Engineering Systems and over 20 years' experience in research engineering, including the role of senior research engineer at the Marconi Research Centre (now BAE Systems Advanced Technology Centre). His specialist area of interest at Marconi was high temperature super conducting microwave circuits. Daniel also worked at University College London as senior research engineer and laboratory manager, where he designed and built specialist human movement and balance investigational equipment. During his career he has received numerous industry awards for his innovation and technology. Daniel joined OrganOx in 2014.
James Broomham Director of Operations Read more
James joined OrganOx in January 2021 as Director of Operations. He has over 15 years experience in operational leadership roles within the Pharmaceutical and Medical Device sectors. Prior to joining OrganOx James worked for Becton Dickinson & Company (BD) as Operational Excellence Manager for Pharmaceutical Systems Advanced Drug Delivery Systems Manufacturing. During James’ 10 years with BD he held roles within Operational Excellence, Manufacturing, Plant Supply Chain, Supply Chain Projects, and Global Supply Chain.
Earlier in his career, he worked at Catalent Pharma, Patheon, and Penn Pharmaceutical Services in a variety of roles within Product Development, Project Management and Operational Excellence.
James holds a First Class Honours Degree in Pharmaceutical Science from London Metropolitan University, and a Masters Degree in Engineering & Management of Manufacturing Systems from Cranfield University. James holds industrial certification as a Lean Six Sigma Green Belt, Lean Leader, Kaizen Leader, and is a Member of the Institute of Management Services.
Chris Morris Global Director of Clinical Support and Training Read more
Chris joined OrganOx in 2014 and leads the Global Clinical Specialist team.
Chris is an active, registered Clinical Perfusion Scientist, with 20 years’ experience in the NHS. Chris trained at King’s College Hospital London, before becoming manager of their Liver Transplant Perfusion team.
Chris currently practices as a Senior Clinical Perfusionist at Oxford’s John Radcliffe Hospital.
Chris’ research interests lie in the in-situ and ex-situ applications of normothermic organ preservation and repair as well as cardiac support.
Rupa Basu SVP North America Operations Read more
Rupa joined OrganOx in 2022 and leads our North American Operations.
With a 25+ year successful track record in the US Health Care industry, Rupa comes to us with experience in large, mid and early stage med tech companies. In 2019, Rupa founded Erineva, a consulting practice focused on advising C-suite and boards of start-ups in the US market. Prior to that, she was responsible for leading and executing the US commercial strategy for Biotronik, a Berlin based international cardiac device company for five years. Rupa spent over 12 years in various roles at St Jude Medical (acquired by Abbott Medical) including leading the corporate accounts team responsible for contracting and selling to the top IDNs and governmental health systems in the US.
Rupa received a BS in Mathematics, Physics and Economics from Punjab University, India and an MBA from Ohio University in the US.
Robert Bovy VP of Regulatory Affairs; North America Read more
Rob joined OrganOx in February 2021. Previously, Rob has worked for a number of start-up companies in the radiation cancer therapy, critical care ventilation and in vitro diagnostics arenas.
Prior to joining OrganOx, Rob served for three years at ProNova Solutions as the Director of Regulatory Affairs and Quality Assurance. Rob has 20 years of experience with quality management systems and regulatory registration submissions in the US, EU, Asia Pacific and South America.
Lucy Randle VP of Clinical Engagement, North America Read more
Lucy joined OrganOx in April 2016 and transferred to the United States in 2018. Lucy leads the North American Clinical Specialist team.
Prior to joining OrganOx, Lucy worked for the University of Cambridge Department of Surgery as a Research Associate involved in a number of transplant related non-clinical and clinical trials, focusing on in situ Normothermic Regional Perfusion, ex situ normothermic liver and kidney perfusion, and the assessment of liver steatosis. Lucy was awarded the Calne-Williams Medal for research in the field of liver transplantation.
Earlier in her career Lucy worked in various clinical and leadership roles within organ donation and transplantation at Cambridge University Hospital NHS Foundation Trust.
Katerina de Metz VP Clinical and Medical Affairs; North America Read more
Katerina joined OrganOx in 2022 and leads our North American Medical and Clinical Affairs initiatives.
Katerina brings more than 20 years of experience in the US med tech industry and prior to joining, worked at Biotronik for 23 years where she held various roles with increasing responsibility in the Clinical Studies and Training and Education departments. Katerina led the Training and Education team to develop and deliver employee and customer programs aligned with business needs and with a focus on quality and accessibility. In her Clinical Studies role Katerina managed numerous IDE Trials, as well as several Post-Approval Trials and Investigator Initiated Clinical Research Studies. Prior to Biotronik, she held a Clinical Research position at Intermedics and was the Medical Physicist at the Nuclear Medicine department of the University Hospital in Brussels.
Katerina has a Master's degree in Physics from the University of Antwerp, Belgium and a Master's degree in Biomedical Engineering from the University of Brussels, Belgium.
OrganOx is at the forefront of changing the way donor livers are preserved in the critical time between donation and transplantation
OrganOx was founded in 2008 as a spin-out from the University of Oxford to advance the normothermic perfusion technology invented by Professor Peter Friend and colleagues, and further developed by Professor Constantin Coussios.
Our first product the metra®, received CE mark approval in 2016 and FDA-approval in 2021. Since then, the metra has supported over 1,500 transplants around the world, transforming the way donor livers are preserved and assessed, and helping to ensure more livers are available for transplantation.
UK/US MD-040-4-1 - September 2022